ES2114882T3 - Acidos hidroxialquilquinolinos insaturados como antagonistas de leucotrienos. - Google Patents

Acidos hidroxialquilquinolinos insaturados como antagonistas de leucotrienos.

Info

Publication number
ES2114882T3
ES2114882T3 ES91309306T ES91309306T ES2114882T3 ES 2114882 T3 ES2114882 T3 ES 2114882T3 ES 91309306 T ES91309306 T ES 91309306T ES 91309306 T ES91309306 T ES 91309306T ES 2114882 T3 ES2114882 T3 ES 2114882T3
Authority
ES
Spain
Prior art keywords
hydroxialkylquinoline
leucotrene
antagonists
acids unsaturated
leucotrene antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91309306T
Other languages
English (en)
Inventor
Michel L Belley
Serge Leger
Patrick Roy
Yi Bin Xiang
Marc Labelle
Daniel Guay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27082671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2114882(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Application granted granted Critical
Publication of ES2114882T3 publication Critical patent/ES2114882T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

LOS COMPUESTOS QUE TIENEN LA FORMULA I: SON ANTAGONISTAS DE LEUCOTRIENO E INHIBIDORES DE LA BIOSINTESIS DE LEUCOTRIENO. ESTOS COMPUESTOS SON UTILES COMO AGENTES ANTIASMATICOS, ANTIALERGICOS, ANTIINFLAMATORIOS Y CITOPROTECTORES. TAMBIEN SON UTILES EN EL TRATAMIENTO DE LA ANGINA, ESPASMO CEREBRAL, NEFRITIS GLOMERULAR, HEPATITIS, ENDOTOXENIA, UVEITIS Y RECHAZO A LOS INJERTOS.
ES91309306T 1990-10-12 1991-10-10 Acidos hidroxialquilquinolinos insaturados como antagonistas de leucotrienos. Expired - Lifetime ES2114882T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59688790A 1990-10-12 1990-10-12
US74188891A 1991-08-08 1991-08-08

Publications (1)

Publication Number Publication Date
ES2114882T3 true ES2114882T3 (es) 1998-06-16

Family

ID=27082671

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91309306T Expired - Lifetime ES2114882T3 (es) 1990-10-12 1991-10-10 Acidos hidroxialquilquinolinos insaturados como antagonistas de leucotrienos.

Country Status (27)

Country Link
EP (1) EP0480717B1 (es)
JP (1) JP2501385B2 (es)
KR (1) KR100227716B1 (es)
CN (1) CN1046711C (es)
AT (1) ATE165088T1 (es)
CA (1) CA2053209C (es)
CY (1) CY2094B1 (es)
CZ (1) CZ281274B6 (es)
DE (2) DE19875039I2 (es)
DK (1) DK0480717T3 (es)
ES (1) ES2114882T3 (es)
FI (2) FI104897B (es)
HK (1) HK1027473A1 (es)
HR (1) HRP930751B1 (es)
HU (2) HU222344B1 (es)
IE (1) IE913609A1 (es)
IL (3) IL117147A0 (es)
LU (1) LU90284I2 (es)
LV (1) LV12187B (es)
MX (1) MX9101551A (es)
NL (1) NL990009I2 (es)
NO (1) NO914004D0 (es)
NZ (1) NZ240194A (es)
PT (1) PT99213B (es)
SI (1) SI9111647B (es)
SK (1) SK279944B6 (es)
YU (1) YU48742B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
CA2111372C (en) * 1992-12-22 2007-01-16 Robert N. Young Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5438141A (en) * 1993-05-21 1995-08-01 Merck Frosst Canada, Inc. Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
ES2080656B1 (es) * 1993-07-19 1996-10-16 Merck Frosst Canada Inc Acidos de hidroxialquilquinolina fluorados como antagonistas del leucotrieno.
CA2130723C (en) * 1993-09-03 2006-01-31 Wilhelm Quittmann Process for preparing y-mercaptocarboxylic acid derivatives
DE4339724C1 (de) * 1993-11-22 1995-01-19 Siemens Ag Gasarmatur
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
CA2145735A1 (en) * 1994-04-21 1995-10-22 Paul Hanselmann Process for producing 5-oxaspiro[2.4]heptan-6-one and novel intermediate products obtained therein
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5750539A (en) * 1995-06-07 1998-05-12 Merck Frosst Canada Heteroaryl diol acids as leukotriene antagonists
US5714488A (en) * 1995-10-03 1998-02-03 Abbott Laboratories Bis-heteroarylylmethoxyphenyl ketone derivatives as inhibitors of leukotriene biosynthesis
US5668150A (en) * 1996-07-26 1997-09-16 Abbott Laboratories Non-symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
FR2751969B1 (fr) * 1996-08-01 1998-12-04 Centre Nat Rech Scient Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6221880B1 (en) 1998-10-09 2001-04-24 Schering Corporation Composition and method for treating allergic diseases
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
DE60310683T2 (de) * 2002-02-06 2007-10-11 Delmar Chemicals Inc., Lasalie Verfahren zur herstellung von 1-(mercaptomethyl)cyclopropan essigsäure
CA2371048C (en) 2002-02-06 2011-01-04 Delmar Chemicals Inc. Process for the preparation of 1-(mercaptomethyl)-cyclopropaneacetic acid
WO2003066598A1 (en) * 2002-02-07 2003-08-14 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
AU2003253247A1 (en) 2003-06-06 2005-01-04 Morepen Laboratories Limited An improved method for the preparation of montelukast acid and sodium salt thereof in amorphous form
JP2007508271A (ja) 2003-10-10 2007-04-05 シントン・ベスローテン・フェンノートシャップ 固体状態のモンテルカスト
EP1709001A2 (en) * 2004-01-28 2006-10-11 Pliva Istrazivanje i Razvoj d.o.o. Solid forms of montelukast acid
EP1760077A1 (en) * 2004-01-30 2007-03-07 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
MXPA06008584A (es) * 2004-01-30 2007-04-16 Teva Pharma Polimorfos de acido libre de montelukast.
WO2005074893A1 (en) 2004-02-03 2005-08-18 Chemagis Ltd. Stable amorphous forms of montelukast sodium
MXPA06012220A (es) 2004-04-21 2007-07-18 Teva Pharma Procesos para preparar sodio de montelukast.
US7829716B2 (en) 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
WO2006008750A2 (en) 2004-07-19 2006-01-26 Matrix Laboratories Ltd Methyl 2-[(3s)-[3-[(2e)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates
WO2006008751A2 (en) * 2004-07-19 2006-01-26 Matrix Laboratories Ltd Process for the preparation of montelukast and its salts
CA2574362A1 (en) * 2004-07-23 2006-01-26 Pliva-Istrazivanje I Razvoj D.O.O. Process
WO2006021974A1 (en) * 2004-08-23 2006-03-02 Morepen Laboratories Limited A process for synthesizing diol (viii)-an intermediate of montelukast sodium
PL205637B1 (pl) * 2004-10-22 2010-05-31 Inst Farmaceutyczny Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
US20080214822A1 (en) * 2004-11-30 2008-09-04 Medichem, S.A. Process For the Preparation of a Leukotriene Antagonist
WO2006131782A1 (en) * 2005-06-07 2006-12-14 Glade Organics Private Limited Process for the manufacture of methyl-2-(3-(2-(7-chloro-2-quinolinyl-ethenyl)-phenyl)-3-oxopropyl) benzoate
US7812168B2 (en) 2005-07-05 2010-10-12 Teva Pharmaceutical Industries Ltd. Purification of montelukast
US20070161796A1 (en) * 2005-11-16 2007-07-12 Ilan Kor-Sade Drying methods of montelukast sodium by azeotropic removal of the solvent
AR057909A1 (es) 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
US8178680B2 (en) 2005-12-13 2012-05-15 Msn Laboratories Limited Process for the preparation of Montelukast and its pharmaceutically acceptable salts
US7572930B2 (en) 2006-02-02 2009-08-11 Chemagis Ltd. Process for preparing 1-(mercaptomethyl)cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof
WO2007096889A2 (en) 2006-02-27 2007-08-30 Chemagis Ltd. Process for preparing montelukast and salts thereof
EP2004609A2 (en) * 2006-03-06 2008-12-24 Farmaprojects, S.A. Process for preparing a leukotriene antagonist
WO2007107297A1 (en) 2006-03-17 2007-09-27 Synthon B.V. Montelukast amantadine salt
EP2004608B1 (en) 2006-04-12 2011-09-14 Glade Organics Private Limited An improved process for the manufacture of montelukast sodium
US20060223999A1 (en) * 2006-05-10 2006-10-05 Chemagis Ltd. Process for preparing montelukast and precursors thereof
GB0614485D0 (en) * 2006-07-21 2006-09-27 Pliva Istrazivanje I Razvoj D Process
EP1886998A1 (en) * 2006-08-09 2008-02-13 Esteve Quimica, S.A. Purification process of montelukast and its amine salts
GB0618703D0 (en) * 2006-09-22 2006-11-01 Almac Sciences Ltd Synthesis of leikotriene compounds
US7700776B2 (en) 2006-10-24 2010-04-20 Formosa Laboratories, Inc. Compounds and preparation for montelukast sodium
WO2008062478A2 (en) 2006-11-20 2008-05-29 Manne Satyanarayana Reddy Improved process for pure montelukast sodium through pure intermediates as well as novel amine salts
US7271268B1 (en) 2006-12-22 2007-09-18 Formosa Laboratories Inc. Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
EP1958936A1 (en) * 2007-02-14 2008-08-20 Inke, S.A. Process for obtaining montelukast
EP1988079A1 (en) * 2007-04-25 2008-11-05 Lonza Ag Process for the preparation of optically active ethenylphenyl-alcohols
PL205444B1 (pl) 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
ES2320077B1 (es) 2007-07-31 2010-02-26 Moehs Iberica, S.L. Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
KR101072896B1 (ko) 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
EP2053043A1 (en) 2007-10-26 2009-04-29 Inke, S.A. Crystalline salt of montelukast
DE102007061630B4 (de) 2007-12-20 2013-07-04 Formosa Laboratories, Inc. Neue Verbindungen und Herstellung von Montelukast-Natrium
CN101817818B (zh) * 2008-03-06 2011-10-26 台耀化学股份有限公司 一种用于制备孟鲁司特钠的化合物
US8207343B2 (en) 2008-05-26 2012-06-26 Laurus Labs Private Limited Process for preparing montelukast and salts thereof
TR200806298A2 (tr) 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
KR101123292B1 (ko) 2008-09-26 2012-03-19 주식회사 엘지생명과학 몬테루카스트 나트륨염의 제조방법
WO2010064109A2 (en) 2008-12-02 2010-06-10 Mayuka Labs Private Limited An improved process for the preparation of montelukast sodium and its intermediates
WO2010107404A1 (en) 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
TW201111392A (en) 2009-06-16 2011-04-01 Schering Corp Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
WO2011004298A1 (en) 2009-07-09 2011-01-13 Alembic Limited Montelukast hexamethylenediamine salt and its use for the preparation of montelukast sodium
EP2287154A1 (en) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast
CN101638381B (zh) 2009-09-02 2012-08-29 鲁南制药集团股份有限公司 孟鲁司特钠中间体的合成方法
US20120215002A1 (en) * 2009-10-09 2012-08-23 Laurent Lefort Synthesis of optically active intermediate for the preparation of montelukast
AU2009357276A1 (en) 2009-12-23 2012-08-09 Pharmathen S.A. Improved process for the preparation of Montelukast and salts thereof
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
KR100990046B1 (ko) * 2010-07-30 2010-10-26 동국제약 주식회사 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
TR201009394A2 (tr) 2010-11-11 2012-06-21 Bi̇lgi̇ç Mahmut Geliştirilmiş montelukast formülasyonları.
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
EP2502910A1 (en) 2011-03-15 2012-09-26 Laboratorios Lesvi, S.L. Camphorsulfonic salt of a key Montelukast intermediate
CN102690229B (zh) * 2011-03-23 2016-06-08 上海相辉医药科技有限公司 一种孟鲁司特钠的合成及其制备中间体
KR20140108627A (ko) * 2011-07-26 2014-09-12 썬 파마 어드밴스트 리서치 컴패니 리미티드 퀴놀린-, 퀸옥살린 또는 벤조티아졸계 시스테이닐 류코트리엔 길항물질 (ltc4)
WO2013077829A1 (en) 2011-11-21 2013-05-30 Mahmut Bilgic Water-soluble pharmaceutical granules
WO2014118796A1 (en) 2013-01-31 2014-08-07 Melody Healthcare Pvt. Ltd. An in-situ process for the preparation of highly pure montelukast sodium
CN104109122B (zh) * 2013-04-16 2017-03-29 浙江奥翔药业股份有限公司 用于合成孟鲁司特的中间体化合物及其制备方法
CN104370810B (zh) * 2013-08-13 2016-10-05 天津汉瑞药业有限公司 孟鲁司特钠化合物
CN103554017B (zh) * 2013-10-25 2014-12-17 河北序能生物技术有限公司 一种孟鲁司特钠手性中间体的制备方法
CN103936671B (zh) * 2014-05-06 2015-10-28 启东东岳药业有限公司 孟鲁司特钠中间体的制备方法
CN105294556A (zh) * 2014-06-06 2016-02-03 上海迪赛诺化学制药有限公司 一种制备孟鲁司特酸的方法
CN105085391B (zh) 2015-06-10 2017-08-22 广东默泰同创医药科技有限公司 用作白三烯受体拮抗剂的环丙基不饱和喹啉化合物及应用
CN108273039B (zh) * 2015-12-16 2021-04-30 新乡医学院第一附属医院 一种治疗溶血性贫血的药物组合物及其应用
CN108530355B (zh) * 2018-06-08 2019-09-10 福州华博立乐新材料科技有限公司 一种3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛的合成方法
CN108435257A (zh) * 2018-06-08 2018-08-24 福州华博立乐新材料科技有限公司 一种用于合成3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛的催化剂
IT201900008340A1 (it) 2019-06-07 2020-12-07 Genetic S P A Sali di montelukast e loro composizioni farmaceutiche

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8801209A1 (es) * 1985-06-18 1988-01-01 Merck Frosst Canada Inc Un procedimiento para la preparacion de quinolinas 2-sustituidas.
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
US4851409A (en) * 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
JPS62258362A (ja) * 1986-05-02 1987-11-10 Terumo Corp アミド誘導体およびこれを含有する５−リポキシゲナ−ゼ作用阻害剤
EP0271287A3 (en) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Quinoline dioic acids and amides
EP0318093A3 (en) * 1987-11-25 1990-12-05 Merck Frosst Canada Inc. Diarylquinoline diacids and their use as medicaments
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof
WO1990015801A1 (en) * 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases

Also Published As

Publication number Publication date
NO914004D0 (no) 1991-10-11
CS309591A3 (en) 1992-04-15
FI104897B (fi) 2000-04-28
CA2053209A1 (en) 1992-04-13
LU90284I2 (fr) 1998-11-03
DE69129257T2 (de) 1998-11-05
JP2501385B2 (ja) 1996-05-29
DE19875039I2 (de) 2003-05-22
CZ281274B6 (cs) 1996-08-14
LV12187A (lv) 1998-12-20
IL117147A (en) 2000-10-31
FI914796L (fi) 1992-04-13
CN1061407A (zh) 1992-05-27
FI914796A0 (fi) 1991-10-11
AU639610B2 (en) 1993-07-29
NZ240194A (en) 1995-03-28
AU8579491A (en) 1992-04-16
NL990009I1 (nl) 1999-06-01
PT99213B (pt) 1999-01-29
NL990009I2 (nl) 1999-07-01
DE69129257D1 (de) 1998-05-20
HK1027473A1 (en) 2001-01-12
HU211294A9 (en) 1995-11-28
CA2053209C (en) 1998-12-08
HRP930751A2 (en) 1995-06-30
MX9101551A (es) 1992-06-05
JPH05105665A (ja) 1993-04-27
KR920008006A (ko) 1992-05-27
EP0480717B1 (en) 1998-04-15
EP0480717A1 (en) 1992-04-15
YU48742B (sh) 1999-09-27
SK279944B6 (sk) 1999-06-11
SI9111647B (en) 2001-06-30
DK0480717T3 (da) 1999-02-08
SI9111647A (en) 1997-12-31
IL99726A (en) 1998-02-22
KR100227716B1 (ko) 1999-11-01
CN1046711C (zh) 1999-11-24
YU164791A (sh) 1994-04-05
HU913217D0 (en) 1992-01-28
IE913609A1 (en) 1992-04-22
IL99726A0 (en) 1992-08-18
CY2094B1 (en) 2002-04-05
ATE165088T1 (de) 1998-05-15
IL117147A0 (en) 1996-06-18
LV12187B (en) 1999-02-20
HU222344B1 (hu) 2003-06-28
FI20000250A7 (fi) 2000-02-07
HRP930751B1 (en) 2000-06-30
PT99213A (pt) 1992-09-30
HUT61981A (en) 1993-03-29

Similar Documents

Publication Publication Date Title
MX9101557A (es) Acidos de hidroxialquilquinolina saturados como antagonistas de leucotrieno.
MX9302033A (es) Acidos de hidroxialquilquinolina fluorados como antagonistas de leucotrieno.
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2147759T3 (es) Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
ES2138622T3 (es) Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
MX9304698A (es) Heterociclos que contienen nitrogeno substituido.
ES2146741T3 (es) Derivados de rapamicina utiles como inmunosupresores.
MX9301634A (es) Quinuclidinas peptidicas.
ES2156934T3 (es) Compuestos que presentan una potente actividad de antagonistas del calcio y de antioxidantes y su utilizacion como agentes citoprotectores.
DK0889886T5 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
MX9101551A (es) Acidos de hidroxialquilquinolina insaturados como antagonistas de leucotrieno
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
PT691128E (pt) Metodos de administracao de antagonistas de crf
ES2130269T3 (es) Oximas sustituidas con piridina, pirrolidina y azepina utiles como agentes contra la aterosclerosis y antihipercolesterolemicos.
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
ES2123873T3 (es) Pirrolocarbazol.
ES2104821T3 (es) Cetoacidos que contienen quinoleina como antagonistas de leucotrienos.
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
ES2092981T3 (es) Derivados de aristeromicina/adenosina.
ES2116496T3 (es) Proceso para la preparacion de 1,4-disubstituido-5(4h)-tetrazolinonas.
ES2145765T3 (es) Acidos heterociclicos 5,6-fusionados diarilicos como antagonistas de leucotrieno.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 480717

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: MONTELUKATS SODICO

Spc suppl protection certif: C9800023

Filing date: 19980901

SPCG Supplementary protection certificate granted

Free format text: MONTELUKAST SODICO

Spc suppl protection certif: C9800023

Filing date: 19980901

Expiry date: 20120825